TOKYO, July 29, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its in-house discovered tyrosine kinase inhibitor, “LENVIMA®” (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, p […]

– Rationalization of domestic production technologies and strengthening of the system in Japan for manufacturing divertor outer vertical targets for ITER– Seeking to contribute to the ITER Project and provide components for the prototype reactor for fusion energy and startup machines TOK […]